Terry Pearson
Directeur Technique/Scientifique/R&D chez Siscapa Assay Technologies, Inc.
Profil
Terry W.
Pearson is currently serving as a Director at CAVA Healthcare, Inc., Director at Science Council of British Columbia, Director at Eyam Vaccines & Immunotherapeutics Ltd., and Chief Scientific Officer at Siscapa Assay Technologies, Inc. Previously, he held positions as a Director at Marker Therapeutics, Inc., Independent Director at biOasis Technologies, Inc., Independent Director at Nevis Brands, Inc., Staff Scientist-Cell Biology Division at the University of British Columbia, Professor at the University of Victoria, and Trustee at The Terry Fox Foundation.
He obtained his undergraduate and doctorate degrees from the University of British Columbia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
inf% | 18/10/2023 | 100 000 ( inf% ) | - $ | Aujourd'hui |
Postes actifs de Terry Pearson
| Sociétés | Poste | Début |
|---|---|---|
| Science Council of British Columbia | Directeur/Membre du Conseil | 01/09/2010 |
CAVA Healthcare, Inc.
 CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Directeur/Membre du Conseil | - |
Siscapa Assay Technologies, Inc.
 Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Directeur Technique/Scientifique/R&D | - |
| Eyam Vaccines & Immunotherapeutics Ltd. | Directeur/Membre du Conseil | 10/01/2022 |
Anciens postes connus de Terry Pearson
| Sociétés | Poste | Fin |
|---|---|---|
| BIOASIS TECHNOLOGIES INC. | Directeur/Membre du Conseil | 21/09/2017 |
| MARKER THERAPEUTICS, INC. | Directeur/Membre du Conseil | 05/12/2005 |
| University of British Columbia | Corporate Officer/Principal | - |
| NEVIS BRANDS INC. | Directeur/Membre du Conseil | - |
| University of Victoria | Corporate Officer/Principal | - |
Formation de Terry Pearson
| University of British Columbia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| NEVIS BRANDS INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Siscapa Assay Technologies, Inc.
Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Health Technology |
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Consumer Non-Durables |
| The Terry Fox Foundation | |
| Science Council of British Columbia | |
| Eyam Vaccines & Immunotherapeutics Ltd. |